

Oliver Grundmann

University of Florida
College of Pharmacy
Department of Medicinal Chemistry
Gainesville, FL 32611

grundman@ufl.edu
352.246.4994 (Cell)
<https://pharmacy.ufl.edu/profile/grundmann-oliver/>
<https://www.linkedin.com/in/olivergrundmann/>

Education

<i>December 2014</i>	Master of Education (MEd) in Educational Technology, University of Florida, US
<i>December 2007</i>	Doctor of Philosophy (PhD) in Pharmaceutical Sciences, University of Florida, US; Dissertation title: Anxiolytic activity of <i>Apocynum venetum</i> L. and its proposed Mechanisms of Action
<i>May 2007</i>	Master of Science (MS) in Forensic Toxicology with Minor in Statistics, University of Florida, US
<i>May 2007</i>	Graduate Certificate in Drug Chemistry, University of Florida
<i>March 2007</i>	Certificate in WebCT Vista and Turnitin for Vista for Instructors, University of Florida
<i>December 2006</i>	Graduate Certificate in Forensic Toxicology, University of Florida
<i>May 2004</i>	Final exam and licensure as pharmacist, Westfälische Wilhelms-Universität Münster, Münster, Germany
<i>February 1998 - November 1999</i>	Certificate in psychological counseling, Academy for Holistic Studies, Haan, Germany

Work Experience

<i>September 2023 - present</i>	Assistant Dean of Lifelong Learning, College of Pharmacy, University of Florida
<i>July 2021 - present</i>	Clinical Professor & Director, Department of Medicinal Chemistry, College of Pharmacy, University of Florida
<i>July 2014 - present</i>	Faculty advisor of online graduate education programs in Pharmaceutical Chemistry & Clinical Toxicology, University of Florida
<i>July 2014 - Jun 2021</i>	Clinical Associate Professor, Department of Medicinal Chemistry, College of Pharmacy, University of Florida
<i>December 2011 - present</i>	Joint appointment as Assistant Professor, Department of Biobehavioral Nursing Science, College of Nursing, University of Florida
<i>May 2011 - present</i>	Adjunct Assistant Professor, Department of Pharmaceutical Sciences, College of Pharmacy, Midwestern University
<i>March 2015 - June 2018</i>	Volunteer in Police Service, Forensic Toxicology & Controlled Substance units, Mesa Police Department
<i>October 2008 - June 2014</i>	Clinical Assistant Professor, Department of Medicinal Chemistry, College of Pharmacy, University of Florida

<i>January 2008 - October 2008</i>	Research Associate, Department of Nutritional Sciences, University of Arizona
<i>June 2007 - October 2008</i>	Teaching assistant (Natural medicinal products, Laboratory QA/QC), Forensic Science Distance Education Program, University of Florida
<i>November 2004 - June 2007</i>	Research assistant, Office of Research Support, College of Nursing, University of Florida
<i>August 2004 - December 2007</i>	Teaching assistant (Pharmaceutical Skills Laboratory, Integrated Case Studies), Department of Pharmaceutics, University of Florida
<i>May 2006 - July 2006</i>	Visiting Scientist, Neurological Science Institute, Oregon Health and Science University
<i>June 2005 - August 2005</i>	Fellow of the Japan Society for the Promotion of Science, Research associate at the University of Tokushima, Japan
<i>November 2004 - February 2005</i>	Consultant for clinical study, Dr. Childress/Dr. Stechmiller, College of Nursing, University of Florida
<i>May 2004 - August 2004</i>	Employed pharmacist in local pharmacy, Lengerich, Germany
<i>November 2003 - April 2004</i>	Internship at Merck KGaA (Quality control and analysis department), Darmstadt, Germany
<i>May 2003 - October 2003</i>	Internship at local pharmacy, Münster, Germany
<i>August 1998 - September 1998</i>	Internship with Wagner Pharmaceuticals (Analytical department), Lengerich, Germany
<i>August 1997 - July 1998</i>	Civil service as nurse aid on internal medicine station in local hospital, Lengerich, Germany

Academic instruction/Teaching

(see anonymous teaching evaluations on <http://www.ratemyprofessors.com/ShowRatings.jsp?tid=1827919>, <https://gatorevals.ua.ufl.edu/public-results/> and <https://evaluations.ufl.edu/results/>)

<i>October 2008 - June 2014</i>	Development, implementation, and teaching of graduate courses in Pharmaceutical Chemistry (PHA5433/6432, PHA5437/6444, PHA5438/PHA6543, PHA6935/PHA6357, PHA6936), Clinical Toxicology (PHA6935/PHA6556, PHA6935/PHA6557, PHA6935, PHA6936), and Forensic Science (PHA6354, PHA6417, PHA6840, PHA6935, VME6766)
<i>July 2014 - current</i>	Administration, development, implementation, and teaching of graduate courses in Pharmaceutical Chemistry (PHA6432, PHA6444, PHA6543, PHA6357, PHA6935, PHA6936), Clinical Toxicology (PHA6556, PHA6557, PHA6935, PHA6936), and Forensic Science (PHA6354, PHA6417, PHA6840, PHA6935)
<i>January 2017 - current</i>	Development and team-teaching of PharmD courses as part of the Patient Care continuing course series (PHA5781, PHA5782, PHA5784, PHA5787, PHA5789)
<i>January 2018 - current</i>	Development, implementation and teaching of undergraduate Honors course (un)common reads: Addiction (IDH2930)

Presentations, Posters, Abstracts, and Invited lectures (excerpt)

1. *September 2023* Self-perceived Differential Effects Of Kratom (*Mitragyna speciosa* Korth.) "Strains" Do Not Correlate With Alkaloid Content, American College of Clinical Pharmacology, Bellevue, WA.
2. *September 2023* The tight rope of substance abuse potential – the pre-clinical and clinical factors that make or break the scheduling of a substance, using Kratom (*Mitragyna speciosa*) as an example, American College of Clinical Pharmacology, Bellevue, WA.
3. *August 2023* An Interdisciplinary Overview on the Increasing Clinical and Scientific Relevance of Kratom, American Psychological Association 2023 Annual Meeting, Washington, DC.
4. *April 2023* Effects after self-administration of typical kratom dose among regular kratom-using adults, American Society of Addiction Medicine 54th Annual Conference, Washington, DC.
5. *October 2022* Associations of concomitant psychiatric disorders and kratom (*Mitragyna speciosa* Korth.) use, IX International Conference on Novel Psychoactive Substances, Hybrid meeting, Panama City, Panama.
6. *June 2022* Comparison of epidemiological data on functional GI diseases under an herbal therapy from non-interventional studies in the US and Germany, Phytotherapie 2022 – innovativ, Zürich, Switzerland.
7. *June 2022* From Bench to Bedside to Policy: Updating Our Understanding of Kratom, The Who, Why, and What: Kratom User Profiles in the US, The College on Drug Problems and Dependence, 2022 Annual Meeting, Minneapolis, MN.
8. *April 2022* The emerging science of Kratom – its benefits, limitations, and the research ahead for an unusual opioid-like herbal product. Kratom Summit 2022, Online.
9. *December 2021* Kratom Use in the Context of Substance Use Disorders and Harm Reduction Strategies. American Society of Health-System Pharmacists, Online.
10. *November 2021* Correlation of self-reported psychiatric disorders, self-report scales, and co-use of substances from an online survey among people who use kratom. VIII International Conference on Novel Psychoactive Substances, Online.
11. *September 2021* Equity through Education: Advancing Careers of Female and Minority Graduates in Online Graduate Programs. OLC Accelerate 2021, Online.
12. *August 2021* Opioid or not – the relevance of Kratom in the context of the opioid crisis. American Academy of Clinical Toxicology webinar, Online.
13. *June 2021* Kratom (*Mitragyna speciosa*) in the context of polydrug use among adults: findings from an international survey & qualitative social media analyses. 83rd Annual Meeting of the College of Problems on Drug Dependence, Online.
14. *March 2021* Pharmacological & phytochemical investigations of Kratom (*Mitragyna speciosa* Korth.) in the nematode *Caenorhabditis elegans*. 87th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT), Online.
15. *January 2021* Scientist Briefing on Kratom Research Policy Change, American Kratom Association Annual Meeting, Online.

16. *November 2020* The Profile of a Kratom Consumer in America, Panel Discussion, Kratom leadership summit, Online.
17. *July 2020* The medico-legal area of Kratom – what we know and what we do not know, American Academy of Clinical Toxicology webinar, Online.
18. *June 2020* Misattribution of Substance Overdose Deaths Can Be Deadly: Lessons from Opioids, Vaping, and Kratom, and a Perspective from HIV/Aids. College on Problems of Drug Dependence, Hollywood, FL.
19. *June 2020* Assessment Of Microbial Load And Heavy Metal Levels In Kratom Samples Purchased In The Western Suburbs Of Chicago. American Society for Microbiology. Chicago, IL.
20. *May 2020* Drug Discovery & Development for SARS-CoV-2 and COVID-19, American Chemical Society Chicago Section webinar, Online.
21. *April 2020* Kratom (*Mitragyna speciosa* Korth.): The tree, the drug, the myths, University of Minnesota, invited lecture for graduate course Use and Abuse of Drugs.
22. *April 2020* Evaluation of the mitragynine content, levels of toxic metals and the presence of microbes in kratom samples purchased in the Western Suburbs of Chicago. American Society of Pharmacology and Experimental Therapeutics. San Diego, CA.
23. *March 2020* Comparison of epidemiological data on functional GI diseases under an herbal therapy from non-interventional studies in the US and Germany. 4th Meeting of the Federation of Neurogastroenterology & Motility. Adelaide, Australia.
24. *February 2020* Comparison of epidemiological data on functional GI diseases under an herbal therapy from non-interventional studies in in the US and Germany. 27th Annual Meeting German Society for Neurogastroenterology and Motility, Freising, Germany.
25. *September 2019* Communicating Your Science: An Integrated Scientific Writing Symposium & Workshop for Early-stage Professionals & Trainees. American College of Clinical Pharmacology. Chicago, IL.
26. *September 2019* Impact of Kratom use on chronic health conditions in US users. American College of Clinical Pharmacology. Chicago, IL.
27. *June 2019* The Impact of Kratom (*Mitragyna speciosa* Korth.) Use on Frequency of Illicit Drug Use and Risky HIV Behaviours among Poly-Drug Users in Malaysia. 81st Annual Scientific Meeting, College on Problems of Drug Dependence. San Antonio, TX.
28. *April 2019* Challenges and Opportunities in the Development and Implementation of QM Standards in International Collaborative Programs in Health Sciences. Quality Matters Regional Conference East, New York, NY.
29. *February 2019* Socio-economic determinants of Kratom use in the US – an important consideration in the scientific discussion. Second International Symposium on Kratom. Orlando, FL.
30. *December 2018* The effects of solvents on mitragynine and 7-hydroxymitragynine extraction from *Mitragyna speciosa*, commonly known as kratom. American Society of Health-System Pharmacists. Anaheim, CA.
31. *September 2018* Kratom use patterns in the United States – state and national trends. American College of Clinical Pharmacology. Bethesda, MD.

32. *August 2018* From Theory to Practice in the Virtual Classroom – Supportive Teaching Tools. 34th Annual Distance Teaching & Learning Conference. University of Wisconsin, Madison, WI.
33. *June 2018* Kratom – from traditional medicine to herbal supplement to drug of abuse and back, an update for healthcare providers about who is using it, who can use it, and why it should (or should not) be regulated. Midwestern University. Midwestern University, Glendale, AZ
34. *June 2018* Acupuncture RCT in patients with GI cancer cachexia: A pilot study. American Society of Clinical Oncology. Chicago, IL.
35. *October 2017* Teaching Collaborations on a Global Level – Vision and Reality, 27th World Conference on Online Learning, Toronto, Canada.
36. *October 2017* Kratom from the user perspective – results from an online survey, North American Congress of Clinical Toxicology, Vancouver, Canada.
37. *August 2017* Integrative medicine as a vehicle for evidence-based recognition of traditional medicine by healthcare providers, 1st International Conference on Natural Medicine, Bangkok, Thailand.
38. *June 2017* Kratom – from traditional medicine to herbal supplement to drug of abuse and back, an update for healthcare providers about who is using it, who can use it, and why it should (or should not) be regulated, Midwestern University Research Seminar Series, Glendale, AZ.
39. *April 2017* The Link between Microbiome Biodiversity and Chronic Disease – the Use of Bioinformatics and Big Data to Find New Drug Targets, Bioinformatics and Proteomics Driven Biomarker Developments-BPDBD Conference 2017 Chitkara University, India, via webcast.
40. *September 2016* Are changes in phase angle and body composition by gender in cancer patients with cachexia different from healthy population?, 3rd International Conference on Cancer Cachexia, Washington, D.C.
41. *June 2016* Active Learning Strategies in Self-Care Pharmacy Education, Advances in Medical Education 2016, Jacksonville, FL.
42. *April 2016* Gender differences in body composition among gastrointestinal cancer patients with unintentional weight loss, 41st Annual Oncology Nursing Society Congress, San Antonio, TX.
43. *February 2016* Active Learning Strategies in Self-Care Pharmacy Education, American Association of Colleges of Pharmacy Interim Meeting, Tampa, FL.
44. *February 2016* Gender differences in body composition among gastrointestinal cancer patients with unintentional weight loss, 30th Annual Conference of the Southern Nursing Research Society, Williamsburg, VA.
45. *October 2015* Evaluation of the affective and cognitive capabilities of paramedics in the United States in assessing and managing toxic alcohol exposures, North American Congress of Clinical Toxicology, San Francisco, CA
46. *May 2015* Detection of bioterrorism agents in highly mobile settings – the path forward for rapid screening, 91st Florida Annual Meeting and Exposition of the American Chemical Society, Tampa, FL

47. *April 2015* Organizing Online Education successfully, Studying in an Online Learning Environment, Technology to enhance student-enriched virtual and blended classrooms, invited lectures, Hoogeschool van Arnhem en Nijmegen, Nijmegen, Netherlands
48. *March 2015* Complementary Therapy Use and its Perceived Influences on Gastrointestinal (GI) Symptoms, UF College of Nursing Research Day, Gainesville, FL
49. *March 2015* The Professor within the Machine – how to teach and learn globally, National Science Teachers Association Annual Global Conversations Conference, Chicago, IL
50. *August 2014* Near or Far – Online and Distance Education Technology at the University of Florida transcends boundaries, International Conference on China-US Open and Distance Education, Beijing, China
51. *August 2014* The Use of Bioelectrical Impedance Analysis (BIA) in Patients with Gastrointestinal Cancer, American Association of Naturopathic Physicians Annual Conference, Phoenix, AZ
52. *June 2014* Oral Vaccines – Challenges and Successes, Hoogeschool van Arnhem en Nijmegen Graduate Seminar, Nijmegen, Netherlands (via Webinar)
53. *May 2014* Not just “gut feelings” – the human gut microbiome in disease and drug metabolism, Hoogeschool van Arnhem en Nijmegen Graduate Seminar, Nijmegen, Netherlands
54. *July 2013* Herbal supplements during pregnancy, UF College of Nursing, Graduate student seminar series
55. *April 2013* Herbal Supplement Use As Symptom Management Of Gastrointestinal Disorders Using An Online Survey, UF College of Nursing Research Day, Gainesville, FL
56. *March 2013* Not just “gut feelings” – the human gut microbiome in disease and drug metabolism, invited keynote address, International Conference on Advances in pharmacological & pharmaceutical approaches to drug discovery & clinical development, Chandigarh, India
57. *December 2012* SCST Session: Science through Application: How Forensic Science can get Kids interested, Workshop coordinator, National Science Teachers Association Regional Conference, Phoenix, AZ
58. *December 2012* Graduate Distance Education Programs: An Evolving Concept with Practical Applications, panelist, NSTA ESP Symposium, ESP: Unique Features of programs that meet “More Emphasis” Features in the NSES, National Science Teachers Association Regional Conference, Phoenix, AZ
59. *November 2012* Acupuncture as a novel intervention to improve appetite in patients with cancers of the gastrointestinal tract, Oncology Nursing Society, Phoenix, AZ
60. *September 2012* Herbal supplements during pregnancy, UF College of Nursing, Graduate student seminar series
61. *July 2012* Endocrine and Antidiabetic drugs, UF College of Nursing, Invited Lecture for course NUR3145
62. *March 2012* Efficacy of Acupuncture to Improve Cancer-related Nutritional Impairment in Patients with Cancers of the Gastrointestinal Tract, UF College of Nursing Research Day, Gainesville, FL

63. *November 2011* Digital Crime Scene Documentation in Forensic Education, 2011, Techno Forensics Conference, Myrtle Beach, US
64. *October 2011* Graduate Distance Education Programs in Forensic Science, Southwestern Association of Forensic Sciences 2011 conference, Houston, US
65. *September 2011* Not just “gut feelings” – the human gut microbiome in disease and drug metabolism, Midwestern University Guest Speaker Seminar Series, Glendale, US
66. *February 2011* Organoleptic evaluation of a liquid placebo compared with a liquid dietary supplement in healthy adults, 25th Annual Conference of the Southern Nursing Research Society, Jacksonville, US
67. *March 2010* Evaluation of a new online international graduate program in pharmaceutical chemistry, 239th American Chemical Society National Meeting, San Francisco, US
68. *September 2009* Online Worldwide Forensic Collaboration that Sparks Educational Innovation, 5th Meeting of the European Association of Forensic Science, Glasgow, UK
69. *January 2009* The influence of gut bacterial microflora on pre-systemic metabolism of drugs – a new dimension, University of Frankfurt, Frankfurt, Germany
70. *September 2008* International Teaching Collaborations in Forensic Sciences, 87th Annual meeting of the German Society of Legal Medicine, Dresden, Germany
71. *May 2008* Depression – overdiagnosed and undertreated, University of Arizona Elective Enrichment Program, Telemedicine, Tucson, US
72. *March 2007* *Apocynum venetum* – new aspects of a traditional plant, Department of Pharmaceutics, University of Florida, US
73. *March 2006* Anxiolytic activity of *Apocynum venetum* and its proposed mechanism(s) of action, Department of Pharmaceutics, University of Florida, Gainesville, US
74. *August 2005* Antioxidant and anxiolytic activities of a leaf extract of *Apocynum venetum* L., 22nd Annual conference of the Medical and Pharmaceutical Society for traditional Japanese and Chinese medicine, Tokyo, Japan
75. *July 2005* *In vivo* experiments in the evaluation of CNS-active natural medicines – an overview, Department of Nutrition and Food science, University of Kobe, Kobe, Japan
76. *April 2004* Concept development for an administrative tool for validation documentation, Merck KGaA, Darmstadt, Germany

Publications

(see profiles on <https://scholar.google.com/citations?user=JrGj4zQAAAAJ&hl=en> and https://www.researchgate.net/profile/Oliver_Grundmann)

2023

1. Not all kratom is equal: The important distinction between native leaf and extract products, O. Grundmann, A. Garcia-Romeu, C.R. McCurdy, A. Sharma, K.E. Smith, M.T. Swogger, S.T. Weiss, *Addiction*, 2023. PMID: 37814405
2. Relevance of dietary supplement use in gastrointestinal cancer-associated cachexia, S.L. Yoon, O. Grundmann, *Nutrients*, 2023. PMID: 37571328
3. Addressing Inequities in Pharmaceutical Education with an FIP toolkit, A. Ubong Etukakpan, N. Uzman, A. Selcuk, G.M. Khalid, O. Grundmann, J.M. Allen, S.A. Arif, L.M. Butler, J.P. Gettig, M.C. Purnell, E. Rosenberg, H. Truong, L. Wade, N. Padayachee, Z. Booth Rubina Shaikh, Y. Choonara, D. Hammoudi Halat, N. Mourad, M. Akel, C. Thompson, R. Altieri, *Pharmacy Education*, 2023. Accepted manuscript.
4. Examining The Psychoactive Differences Between Kratom Strains, G. Huisman, M. Menke, O. Grundmann, R. Schreiber, N. Mason, *International Journal of Environmental Research and Public Health*, 2023. PMID: 37510657
5. Prevalence, Characteristics, and Reasons for Kratom Use among Psychiatrically Ill Inpatients Who Use Substances, C.N. Stanciu, S. Ahmed, Z. Sarfraz, N. Nimavat, C.J. Healey, O. Grundmann, J.R. Ballard, J. Henningfield, *Journal of Dual Diagnosis*, 2023. PMID: 38153407
6. Correlations of Kratom (*Mitragyna speciosa* Korth.) Tea Bag Preparations and Reported Pharmacological Effects, O. Grundmann, K. Hill, E. Al Barzanji, N.G. Hazrat, G. Kaur, R.E. Negeve, S. Shade, S. Weber, C.A. Veltri, *Journal of Ethnopharmacology*, 2023. PMID: 37364801
7. Biomarkers and Mechanisms Associated with Cancer-Induced Cardiac Cachexia: A Systematic Review, L. Bagnall, S.L. Yoon, O. Grundmann, M.G. Teolis, *Journal of Cachexia, Sarcopenia and Muscle*, 2023. PMID: 37211636
8. Kratom (*Mitragyna speciosa*): Pharmacology and Use of a Naturally Occurring Atypical Opioid, K.E. Smith, O. Grundmann, M.T. Swogger, A. Garcia-Romeu, in: *The Oxford Handbook of Opioids and Opioid Use Disorder*, K.E. Dunn (ed.), 2023. <https://doi.org/10.1093/oxfordhb/9780197618431.013.15>
9. The Utilization and Development of Viral Vectors in Vaccines as a Prophylactic Treatment Against Ebola Virus as an Emerging and Zoonotic Infectious Disease, A. Garcia, O. Grundmann, *Mini-Reviews in Medicinal Chemistry*, 2023. PMID: 37489781
10. Examining the paradoxical effects of kratom: A narrative inquiry, K.E. Smith, J.D. Feldman, K.E. Dunn, C.R. McCurdy, S.T. Weiss, O. Grundmann, A. Garcia-Romeu, J. Nichols, D. Epstein, *Frontiers in Pharmacology*, 2023. PMID: 37214465
11. Novel methods for the remote investigation of emerging substances: Application to kratom, K.E. Smith, J.D. Feldman, K.E. Dunn, C.R. McCurdy, O. Grundmann, A. Garcia-Romeu, L.V. Panlilio, J.M. Rogers, A. Sharma, S. Pont-Fernandez, M. Kheifets, D.H. Epstein, *Experimental and Clinical Psychopharmacology*, 2023. PMID: 37213182
12. Evaluating Health Information Provided to Kratom Consumers by Good Manufacturing Practice-Qualified Vendors, K. Hill, S. Gibson, O. Grundmann, K.E. Smith, J. Ballard, C.N. Stanciu, *Substance Abuse Treatment, Prevention, and Policy*, 2023. PMID: 37041624

2023 Continued

13. Kratom Withdrawal: Discussions and Conclusions of a Scientific Expert Forum, J.E. Henningfield, M.C. Chawarski, A. Garcia-Romeu, O. Grundmann, N. Harun, Z. Hassan, C.R. McCurdy, L.R. McMahon, A. Sharma, M. Shoaib, D. Singh, K.E. Smith, M.T. Swogger, B. Vicknasingam, Z. Walsh, D.W. Wang, M.A. Huestis, *Drug and Alcohol Dependence Reports*, 2023. PMID: 37397437
14. Diagnostic ambiguities and underuse of clinical assessment tools a systematic review of case reports on kratom addiction and physical dependence, J.D. Feldman, D. Schriefer, K.E. Smith, S.T. Weiss, G. Butera, K.E. Dunn, O. Grundmann, C.R. McCurdy, D. Singh, D.H. Epstein, *Current Addiction Reports*, 2023. Accepted manuscript.
15. Omissions, Ambiguities, and Underuse of Causal Assessment Tools: a Systematic Review of Case Reports on Patients Who Use Kratom, J.D. Feldman, D. Schriefer, K.E. Smith, S.T. Weiss, G. Butera, K.E. Dunn, O. Grundmann, C.R. McCurdy, D. Singh, D.H. Epstein, *Current Addiction Reports*, 2023. Accepted manuscript.
16. Editorial: Education in ethnopharmacology 2022, O. Grundmann, D. Lobine, J.O. Olopade, *Frontiers in Pharmacology*, 2023. PMID: 36843942
17. Subclinical vitamin C plasma levels associated with increased risk of CAD diagnosis via inflammation: Results from the NHANES 2003–2006 surveys, J.M. Crook, S.L Yoon, A. Horgas, O. Grundmann, V. Johnson-Mallard, *Nutrients*, 2023. PMID: 36771290
18. Kratom Alkaloids: A Blueprint? K.E. Smith, A. Sharma, O. Grundmann, C.R. McCurdy, *ACS Chemical Neuroscience*, 2023. PMID: 36594896
19. Correlations of Kratom (*Mitragyna speciosa* Korth.) Use Behavior and Psychiatric Conditions from a cross-sectional survey, O. Grundmann, C.A. Veltri, S. Morcos, D. Knightes 3rd, K.E. Smith, D. Singh, O. Corazza, E. Cinosi, G. Martinotti, Z. Walsh, M.T. Swogger, *Experimental and Clinical Psychopharmacology*, 2023. PMID: 36634016

2022

20. Racial, ethnicity and religious inequities, J.M. Allen, S.A. Arif, L.M. Butler, J.P. Gettig, M.C. Purnell, E. Rosenberg, H.-A. Truong, L. Wade, O. Grundmann, in FIP toolkit for addressing inequities in pharmaceutical education, N. Uzman, A. Etukakpan, C. Duggan (eds.), *International Pharmaceutical Federation*, 2022. <https://www.fip.org/inequitiesineducation>
21. A Novel Measure of Pain Location in Adults with Sickle Cell Disease. K. Abudawood, S.L. Yoon, Y. Yao, O. Grundmann, M.O. Ezenwa, R.E. Molokie, D.J. Wilkie, *Pain Management Nursing*, 2022. PMID: 36261305
22. The importance of diversity and inclusion in drug development and clinical trial conduct. K.T. Moore, O. Grundmann, O. Iwuchukwu, N. Rakhmanina, *Journal of Clinical Pharmacology*, 2022. PMID: 36074047
23. Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature. C. Stanciu, S. Ahmed, S. Gnanasegaram, S. Gibson, T. Penders, O. Grundmann, C. McCurdy, *The American Journal of Drug and Alcohol Abuse*, 2022. PMID: 36001875
24. Kratom use as more than a “self-treatment”. K.E. Smith, K.E. Dunn, J.M. Rogers, O. Grundmann, C.R. McCurdy, A. Garcia-Romeu, D. Schriefer, M.T. Swogger, D.H. Epstein, *The American Journal of Drug and Alcohol Abuse*, 2022. PMID: 35767669
25. Kratom: History, pharmacology, current user trends, adverse health effects and potential benefits. O. Grundmann, R.G. Hendrickson, M.I. Greenberg, *Disease-a-month*, 2022. PMID: 35732553

26. Response to Letter to the Editor: "Misstatements in Artemisinin-based Combination Therapies in Malaria Treatment" by Fleckenstein & Miller. J. Hernandez Maldonado, O. Grundmann, *Journal of Clinical Pharmacology*, 2022. PMID: 35727710
27. Need for clarity and context in case reports on kratom use, assessment, and intervention. K.E. Smith, K.E. Dunn, D.H. Epstein, J.D. Feldman, A. Garcia-Romeu, O. Grundmann, J.E. Henningfield, C.R. McCurdy, J.M. Rogers, D. Schriefer, D. Singh, S.T. Weiss, *Substance Abuse*, 2022;43(1):1221-1224. PMID: 35657649
28. Acute, Sublethal, and Developmental Toxicity of Kratom (*Mitragyna speciosa* Korth.) Leaf Preparations on *Caenorhabditis elegans* as an Invertebrate Model for Human Exposure. S. Hughes, D. van de Klashorst, C.A. Veltri, O. Grundmann, *International Journal of Environmental Research and Public Health*, 2022. PMID: 35627831
29. Drug-drug Interactions of Artemisinin-based Combination Therapies in Malaria Treatment: A narrative review of the literature. J. Hernandez Maldonado, O. Grundmann, *Journal of Clinical Pharmacology*, 2022. PMID: 35543380
30. Taking Action Towards Equity, Diversity, and Inclusion in the Pharmacy Curriculum and Continuing Professional Development. S.A. Arif, L.M. Butler, J.P. Gettig, M.C. Purnell, E. Rosenberg, H. Truong, L. Wade, O. Grundmann, *American Journal of Pharmaceutical Education*, 2022. PMID: 35470170
31. Exploring the self-reported motivations of kratom (*Mitragyna speciosa* Korth.) use: a cross-sectional investigation. O. Grundmann, C.A. Veltri, D. Morcos, D. Knightes 3rd, K.E. Smith, D. Singh, O. Corazza, E. Cinosi, G. Martinotti, Z. Walsh, M.T. Swogger, *The American Journal of Drug and Alcohol Abuse*, 2022. PMID: 35389321
32. Editorial: The Pharmacology of Kratom and Its Alkaloids. O. Grundmann, C.R. McCurdy, D. Singh, K.E. Smith, M.T. Swogger, *Frontiers in Pharmacology*, 2022. PMID: 35370662
33. Vitamin C Plasma Levels Associated with Inflammatory Biomarkers, CRP and RDW: Results from the NHANES 2003-2006 Surveys. J.M. Crook, A.L. Horgas, S.L. Yoon, O. Grundmann, V. Johnson-Mallard, *Nutrients*, 2022. PMID: 35334908
34. Understanding Kratom Use: A Guide for Healthcare Providers. M.T. Swogger, K.E. Smith, A. Garcia-Romeu, O. Grundmann, C.A. Veltri, J. Henningfield, L.Y. Busch, *Frontiers in Pharmacology*, 2022. PMID: 35308216
35. Searching for a signal: Self-reported kratom dose-effect relationships among a sample of US adults with regular kratom use histories. K.E. Smith, B.S. Rogers, K.E. Dunn, O. Grundmann, C.R. McCurdy, D. Schriefer, D. Epstein, *Frontiers in Pharmacology*, 2022. PMID: 35300296
36. How essential is Kratom Availability and Use during COVID-19? Use Pattern Analysis based on Survey and Social Media Data, O. Grundmann, C. A. Veltri, D. Morcos, D. Knightes III, K. E. Smith, J. M. Rogers, *Substance Abuse*, 2021. PMID: 35179453
37. We Need Better Estimates of Kratom Use Prevalence. J. E. Henningfield, O. Grundmann, A. Garcia-Romeu, M. Swogger, *American Journal of Preventive Medicine*, 2022. PMID: 34922651
38. Regulation of Dietary Supplements and Nutraceutical Products in the United States: An Argument for Greater Oversight and Uniform Standards, O. Grundmann, P. Kumar, M. Rogge, *Journal of Clinical Pharmacology*, 2022. PMID: 34648654

2022 Continued

39. Front-Line Healthcare Professionals Lack Critical Knowledge in Dietary Supplement and Nutraceutical Products: A Call to Action for Comprehensive Educational Opportunities, M. Rogge, P. Kumar, O. Grundmann, *Journal of Clinical Pharmacology*, 2022. PMID: 34648667

2021

40. Insufficient Vitamin C Levels among Adults in the United States: Results from the NHANES Surveys, 2003–2006, J.M. Crook, A. Horgas, S. Yoon, O. Grundmann, V. Johnson-Mallard, *Nutrients*, 2021. PMID: 34836166
41. Kratom Use Within the Context of the Evolving Opioid Crisis and the COVID-19 Pandemic in the United States. W. C. Prozialeck, P. C. Lamar, M. Krupp 2nd, M. Moon, L. E. Phelps, O. Grundmann, *Frontiers in Pharmacology*, 2021. PMID: 34512353.
42. Social, psychological, and substance use characteristics of US adults who use kratom: initial findings from an online, crowdsourced study. K. E. Smith, K. E. Dunn, O. Grundmann, A. Garcia-Romeu, J. M. Rogers, M. T. Swogger, D. H. Epstein, *Experimental and Clinical Psychopharmacology*, 2021. PMID: 34735202
43. Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use. K. E. Smith, J. M. Rogers, D. Schrieffer, O. Grundmann, *Drug and Alcohol Dependence*, 2021. PMID: 34216869.
44. Clinical Pharmacology, toxicity, and abuse potential of opioids. D. Vearrier, O. Grundmann, *Journal of Clinical Pharmacology*, 2021. PMID: 34396552.
45. Kratom use in the United States: a diverse and complex profile. O. Grundmann, J. K. Babin, J. E. Henningfield, A. Garcia-Romeu, A. C. Kruegel, W. C. Prozialeck, R. B. Raffa, D. Singh, K. E. Smith, *Addiction*, 2021. 116(1):202-203. PMID: 32602213.
46. Is kratom (*Mitragyna speciosa* Korth.) use associated with ECG abnormalities? Electrocardiogram comparisons between regular kratom users and controls. M. F. I. L. Abdullah, K. L. Tan, S. Narayanan, N. Yuvashnee, N. J. Y. Chear, D. Singh, O. Grundmann, J. E. Henningfield, *Clinical Toxicology (Phil.)*, 2021. PMID: 32870119.
47. The Use of Kratom (*Mitragyna speciosa* Korth.) Among People Who Co-use Heroin and Methamphetamine in Malaysia. D. Singh, S. Narayanan, B. Vicknasingam, W. C. Prozialeck, K. E. Smith, O. Corazza, J. E. Henningfield, O. Grundmann, *Journal of Addiction Medicine*, 2021. doi: 10.1097/ADM.0000000000000876
48. Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19). H. Al-Kamel, O. Grundmann, *Mini-Reviews in Medicinal Chemistry*, 2021. PMID: 33568033.
49. STEM Education as a Vital Preventive Response to a Pandemic. K. Baker, E. Faulconer, O. Grundmann, S. Haines, T. Hall-Pogar, L. Kenyon, S. M. Kelly, P. Lindeman, B. Schmaefsky, C. Timpfe, D. Wojnowski, *Journal of College Science Teaching*, 2021. 50(4):3-4.
50. The Burden of The Serious and Difficult-to-treat Infections and a New Antibiotic Available: Cefiderocol. A. Maroyi, Y. Taheri, N. Joković, J. Vitorović, O. Grundmann, D. Calina, *Frontiers in Pharmacology*, 2021. 11, 1922. PMID: 33628170.

2020

51. Current and Future Potential Impact of COVID-19 on Kratom (*Mitragyna speciosa* Korth.) Supply and Use. D. Singh, P. N. Brown, E. Cinosi, O. Corazza, J. E. Henningfield, A. Garcia-Romeu, C. R. McCurdy, L. R. McMahon, W. C. Prozialeck, K. E. Smith, M. T. Swogger, C. Veltri, Z. Walsh, O. Grundmann, *Frontiers in Psychiatry*, 2020. 11, 1355. PMID: 33324252.

2020 continued

52. Can Kratom (*Mitragyna speciosa*) alleviate COVID-19 pain? A Case Study. A. Metastasio, P. Elizabeth, D. Singh, O. Grundmann, W. Prozialek, C. Veltri, G. Bersani, O. Corazza, *Frontiers in Psychiatry*, 2020. 11, 1298. PMID: 33329145.
53. Cachexia in Patients with Gastrointestinal Cancers: Contributing Factors, Prevention, and Current Management Approaches. O. Grundmann, S. L. Yoon, J. J. Williams, *European Medical Journal Gastroenterology*, 2020;9[1]:62-70.
54. Gastrointestinal Inflammation and the Gut Microbiome: An Evolving Conceptual Framework with Implications for Diagnosis and Therapy in Inflammatory Bowel Disorders. O. Grundmann, *European Medical Journal Microbiology and Infectious Diseases*, 2020;1[1]:42-50.
55. Evaluation of the Mitragynine Content, Levels of Toxic Metals and the Presence of Microbes in Kratom Products Purchased in the Western Suburbs of Chicago. W. C. Prozialek, J. R. Edwards, P. C. Lamar, B. J. Plotkin, I. M. Sigar, O. Grundmann, C. A. Veltri, *International Journal of Environmental Research and Public Health*, 2020. PMID: 32751712.
56. The Potential for Kratom as an Antidepressant and Antipsychotic. L. E. Johnson, L. Balyan, A. Magdalany, F. Saeed, R. Salinas, S. Wallace, C. A. Veltri, M. T. Swogger, Z. Walsh, O. Grundmann, *Yale Journal of Biology and Medicine*, 2020. PMID: 32607089.
57. Self-Report Data on Regular Consumption of Illicit Drugs and HIV Risk Behaviors after Kratom (*Mitragyna speciosa* korth.) Initiation among Illicit Drug Users in Malaysia. A. Saref, S. Suraya, D. Singh, O. Grundmann, S. Narayanan, M. T. Swogger, W. C. Prozialek, E. Boyer, V. Balasingam, *Journal of Psychoactive Drugs*, 2020. PMID: 31682782.
58. Public Perceptions toward Kratom (*Mitragyna speciosa*) Use in Malaysia. D. Singh, S. Narayanan, S. Suraya, A. Saref, O. Grundmann, W. C. Prozialek, O. Corazza, M. T. Swogger, O. Griffin III, V. Balasingam, *Journal of Psychoactive Drugs*, 2020. PMID: 32153252.
59. The Pharmacist as an LGBTQ+ Ally. O. Grundmann, R. Segal, J. Pullo, L. Davis, Y. Felix-Irizarry, L. Da Silva, T. Holets, *American Journal of Pharmaceutical Education*, 2020. PMID: 32773835.

2019

60. Critique of "Kratom Use and Toxicities in the United States". O. Grundmann, P.N. Brown, E.W. Boyer, M.T. Swogger, Z. Walsh, W. Prozialek, A.C. Kruegel, C. A. Veltri, S. Dudley, *Pharmacotherapy*, 2019. PMID: 31729073.
61. Risk of Death Associated With Kratom Use Compared to Opioids. J.E. Henningfield, O. Grundmann, J.K. Babin, R.V. Fant, D.W. Wang, E.J. Cone, *Preventive Medicine*, 2019. PMID: 31647958.
62. Effects of Kratom (*Mitragyna speciosa* Korth.) Use in Regular Users. D. Singh, S. Narayanan, O. Grundmann, E.B. Dzulapli, B. Vicknasingam, *Substance Use & Misuse*, 2019. PMID: 31347441.
63. Distinct kratom user populations across the United States: A regional analysis based on an online survey. J.A. Nicewonder, A.F. Buros, C.A. Veltri, O. Grundmann, *Human Psychopharmacology: Clinical and Experimental*, 2019. PMID: 31347212.
64. Current perspective on the impact of Kratom use. C.A. Veltri, O. Grundmann, *Journal Substance Abuse and Rehabilitation*, 2019. PMID: 31308789.

2019 continued

65. The Use of Benzodiazepines among Kratom (*Mitragyna Speciosa* Korth.) Users. D. Singh, S. Narayanan, O. Grundmann, E.W. Boyer, B. Vicknasingam, *Journal of Psychoactive Drugs*, 2019. PMID: 31218929.
66. Kratom Policy: The Challenge of Balancing Therapeutic Potential with Public Safety. W.C. Prozialeck, B.A. Avery, E.W. Boyer, O. Grundmann, J.E. Henningfield, A.C. Kruegel, L.R. McMahon, C.R. McCurdy, M.T. Swogger, C.A. Veltri, D. Singh, *International Journal of Drug Policy*, 2019. PMID: 31103778.
67. Self-reported prevalence and severity of opioid and kratom (*Mitragyna speciosa korth.*) side effects. A. Saref, S. Suraya, D. Singh, O. Grundmann, S. Narayanan, M.T. Swogger, W.C. Prozialeck, E. Boyer, N.J.Y. Chear, V. Balasingam, *Journal of Ethnopharmacology*, 2019. PMID: 31014959.
68. Non-prescribed buprenorphine use mediates the relationship between heroin use and kratom use among a sample of polysubstance users. K.E. Smith, A.M. Bunting, R. Walker, M.T. Hall, O. Grundmann, O. Castillo, *Journal of Psychoactive Drugs*, 2019. PMID: 30961450.
69. Patient Safety, O. Grundmann, E. Ko, K. Ulbricht, in: *Clinical Pharmacognosy Series: Principles and Practice of Botanicals as an Integrative Therapy*, 1st edition, Anne Hume, Katherine Kelly Orr (ed.), 2019, ISBN: 978-1-498-77114-6, CRC Press.
70. Association of Kratom Use with Impairment: Many Legal Questions Remain. C. Veltri, O. Grundmann, *Journal of Analytical Toxicology*, 2019. PMID: 30855680.
71. Augmentation of Cancer Cachexia Components With Targeted Acupuncture in Patients With Gastrointestinal Cancers: A Randomized Controlled Pilot Study. O. Grundmann, S.L. Yoon, J.J. Williams, L. Gordan, T.J. George Jr., *Integrative Cancer Therapies*, 2019. PMID: 30791747.

2018

72. Constipation prevalence and fatigue severity in regular kratom (*Mitragyna speciosa* Korth.) users. D. Singh, T. Damodaran, W.C. Prozialeck, O. Grundmann, T. Karunakaran, B. Vicknasingam, *Journal of Substance Use*, 2018. Accepted manuscript.
73. Complementary, alternative, and integrative therapies in cancer care, C.E. Ulbricht, O. Grundmann, E. Ko, N. Sangave in: *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology*, 11th edition, Vincent T. DeVita, Steven A. Rosenberg, Theodore S. Lawrence (ed.), 2018, ISBN: 978-1-496-39464-4, Wolters Kluwer.
74. Gastrointestinal symptom improvement from fiber, STW 5, peppermint oil, and probiotics use-Results from an online survey. O. Grundmann, S.L. Yoon, S.R. Mason, K.F. Smith, *Complementary Therapies in Medicine*, 2018. PMID: 30477844.
75. Body composition changes differ by gender in stomach, colorectal, and biliary cancer patients with cachexia: Results from a pilot study. S.L. Yoon, O. Grundmann, J.J. Williams, L. Gordan, T.J. George Jr, *Cancer Medicine*, 2018. PMID: 29971962.
76. Dietary Supplement and Complementary and Alternative Medicine Use Are Highly Prevalent in Patients with Gastrointestinal Disorders: Results from an Online Survey. S.L. Yoon, O. Grundmann, K.F. Smith, S.R. Mason, *Journal of Dietary Supplements*, 2018. PMID: 29958032.
77. The therapeutic potential of Kratom. O. Grundmann, P.N. Brown, J. Henningfield, M. Swogger, Z. Walsh, *Addiction*, 2018. PMID: 29949213.

2018 continued

78. Assessment of gonadotropins and testosterone hormone levels in regular *Mitragyna speciosa* (Korth.) users. D. Singh, V. Murugaiyah, S.B.S. Hamid, V. Kasinather, M.S.A. Chan, E.T.W. Ho, O. Grundmann, N.J.Y. Chear, S.M. Mansor, *Journal of Ethnopharmacology*, 2018. PMID: 29626673.
79. Pregnancy and herbal medicines: An unnecessary risk for women's health-A narrative review, L.O. Bruno, R.S. Simoes, M. de Jesus Simoes, M.J.B.C. Girão, O. Grundmann, *Phytotherapy Research*, 2018. PMID: 29417644.
80. The development and impact of active learning strategies on self-confidence in a newly designed first-year self-care pharmacy course – outcomes and experiences. K.J. Smith, O. Grundmann, R. Moorman Li, *Currents in Pharmacy Teaching and Learning*, 2018, 10(4):499-504. PMID: 29793713.

2017

81. The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse, A.C. Kruegel, O. Grundmann, *Neuropharmacology*, 2017, S0028-3908(17):30393-3. PMID: 28830758.
82. Patterns of Kratom use and health impact in the US – Results from an online survey, O. Grundmann, *Drug and Alcohol Dependence*, 2017, 176:63-70. PMID: 28521200.
83. Preclinical and Potential Applications of Common Western Herbal Supplements as Complementary Treatment in Parkinson's Disease, L. Morgan, O. Grundmann, *Journal of Dietary Supplements*, 2017, 14(4):453-466. PMID: 28095073.
84. Pharmacology and Structure-Activity Relationship of Natural Products with psychoactive Effects from *Salvia divinorum*, *Mitragyna speciosa*, and Ayahuasca, S.M. Phipps, O. Grundmann, in: *Studies in Natural Products Chemistry*, Bioactive Natural Products, Volume 53, Atta-Ur-Rahman (ed.), 2017, ISBN: 978-0-444-63930-1, Elsevier Science Publishers.
85. Evaluating the Knowledge Base and current Training of Paramedics in the Southwest United States in Assessing and Managing Toxic Alcohol Exposures, C. Bare, O. Grundmann, *Australasian Journal of Paramedicine*, 2017.
86. Malnutrition & cachexia and influence on quality of life in patients with cancer, O. Grundmann, S.L. Yoon, J.J. Williams, in: *Handbook of Famine, Starvation, and Nutrient Deprivation: from Biology to Policy*, Victor Preedy (ed.), 2017, ISBN 978-3-319-55388-7, Springer Nature.
87. *In Vitro* Assays in Natural Products Research—A Matter of Concentration and Relevance to *In Vivo* Administration Using Resveratrol, α -mangostin/ γ -mangostin, and Xanthohumol as Examples, C. Willson, O. Grundmann, *Natural Products Research*, 2017, 31(5):492-506. PMID: 27234135.

2016

88. Review of Various Herbal Supplements as Complementary Treatments for Oral Cancer, J. Godsey, O. Grundmann, *Journal of Dietary Supplements*, 2016, 13(5):539-550. PMID: 26863913.
89. The pharmacology and toxicology of Kratom: from traditional herb to drug of abuse, M. Warner, N. Kaufman, O. Grundmann, *International Journal of Legal Medicine*, 2016, 130(1):127-138. PMID: 26511390.

2016 continued

90. The use of complementary and alternative medicines in psychiatric disorders, D. Thrower, O. Grundmann, in *Alternative Medicine: Perceptions, Uses and Benefits and Clinical Implications*, P. Cherniak (ed.), 2016, Nova Publishers, ISBN: 9781634848510.

2015

91. The value of bioelectrical impedance analysis and phase angle in the evaluation of malnutrition and quality of life in cancer patients – a comprehensive review, O. Grundmann, S. Yoon, J. Williams, *European Journal of Clinical Nutrition*, 2015, December;69(12):1290-1297. PMID: 26220573.
92. The Physicochemical and Pharmacokinetic Relationships of Barbiturates – from the past to the future, B. Ernst, G. Clark, O. Grundmann, *Current Pharmaceutical Design*, 2015, 21(25):3681-3691. PMID: 25824249.
93. Novel intervention with acupuncture for anorexia and cachexia in patients with gastrointestinal tract cancers: a feasibility study, S. Yoon, O. Grundmann, J. Williams, G. Carriere, *Oncology Nursing Forum*, 2015, 42(2):E102-109. PMID: 25806891.
94. World Clinical Irritable Bowel Syndrome, 1st edition, O. Grundmann (ed.), Baishideng Publishing Group, Pleasonton, CA, February 2015.
95. Mitochondriotropic nanoemulsified genistein-loaded vehicles for cancer therapy, J. Pham, O. Grundmann, T. Elbayoumi, *Methods in Molecular Biology*, 2015, 1265:85-101. PMID: 25634269.
96. Influence of acupuncture on bioelectrical impedance measures in patients with gastrointestinal cancer: results of a pilot study, O. Grundmann, S. Yoon, J. Williams, *Acupuncture in Medicine*, 2015, 33(1):16-22. PMID: 25413610.

2014

97. The current state of bioterrorist attack surveillance and preparedness in the US, O. Grundmann, *Risk Management and Healthcare Policy*, 2014, 9(7):177-187. PMID: 25328421.
98. Complementary and alternative medicines in irritable bowel syndrome: An integrative view, O. Grundmann & S. Yoon, *World Journal of Gastroenterology*, 2014, January;20(2):346-362. PMID: 24574705.
99. A brief Review of Krill oil History, Research and the commercial market, J. Kwantes, O. Grundmann, *Journal of Dietary Supplements*, 2013, March;12(1):23-35. PMID: 24689485.

2013

100. Career Readiness: an Old Idea Revived? (guest editorial), O. Grundmann, *Journal of College Science Teaching*, 2013, doi: 10.2505/4/jcst13_043_01_8.
101. Factors that influence the variability of anogenital injury in adult sexual assault: a review of the forensic literature, F.A. Laitinen, O. Grundmann, E.J. Ernst, *American Journal of Forensic Medicine and Pathology*, 2013, September;34(3):286-294. PMID: 23835534.
102. Mind-body therapies for functional bowel disorders - a review of recent clinical trials, O. Grundmann, S. Yoon, *European Journal of Integrative Medicine*, 2013, August;5(4):296-307. doi: 10.1016/j.eujim.2013.03.007.

2013 continued

103. Recent Advances in the Diagnosis and Treatment of Irritable Bowel Syndrome, O. Grundmann, *Journal of Gastroenterology and Hepatology Research*, 2013, March;2(3):391-393.
104. Menthol – pharmacology of an important naturally medicinal “cool”, J.A. Farco, O. Grundmann, *Mini-Reviews in Medicinal Chemistry*, 2013, January;13(1):124-131. PMID: 23061635.

2012

105. Graduate Distance Education Programs in Forensic Sciences, Pharmaceutical Chemistry, and Clinical Toxicology for Working Professionals: An Evolving Concept with Practical Applications, O. Grundmann, D. Lebow, in *National Science Teachers Association Exemplary Science Program monograph series*, Robert Yager (ed.), NSTA press, ISBN: 9781938946097.
106. An Orthomolecular Approach to the Prevention and Treatment of Psychiatric Disorders, M. Zell, O. Grundmann, *Advances in Mind-Body Medicine*, 2012, Fall;26(2):14-29. PMID: 23341413.
107. Clinical Evaluation of liquid placebos for an herbal supplement, STW5, in healthy volunteers, S. Yoon, O. Grundmann, D. Keane, T. Urbano, B. Moshiree, *Complementary Therapies in Medicine*, 2012, October;20(5):267-274. PMID: 22863640.
108. Aloe vera gel research review, O. Grundmann, *Natural Medicine Journal*, 2012, September;9(4).
109. Recent developments in the Use of Pre- and Probiotics for Irritable Bowel Syndrome, S. Yoon, B. Moshiree, O. Grundmann, *European Gastroenterology & Hepatology Review*, 2012, January;7(4):237-241.

2011

110. The Use of Glucosamine, Devil's Claw (*Harpagophytum procumbens*), and Acupuncture as Complementary and Alternative Treatments for Osteoarthritis, M. Sanders, O. Grundmann, *Alternative Medicine Review*, 2011, September;16(3):228-238. PMID: 21951024.
111. Educational Collaboration for a global Forensic Science Initiative, O. Grundmann, D. Wielbo, N. Toffolo, I. Tebbett, *Forensic Technology Review*, 2011, 210-214.
112. Specialization and multidiscipline approaches in Forensic Science Education – new frontiers, O. Grundmann, D. Wielbo, N. Toffolo, I. Tebbett, *Forensic Technology Review*, 2011, 216-218.
113. Management of Irritable Bowel Syndrome (IBS) in Adults: Conventional and Complementary/Alternative Approaches, S. Yoon, O. Grundmann, L. Koepp, L. Farrell, *Alternative Medicine Review*, 2011, June;16(2):134-151. PMID: 21649455. 2011 continued
114. Remembering the Past and looking forward into the Future (editorial), O. Grundmann, *Alternative Medicine Studies*, 2011, January;1(1).
115. Recent Advances in the Prevention of Bioterrorism Attacks (editorial), O. Grundmann, *Journal of Bioterrorism & Biodefense*, 2011, January;2(1):1.

2011 continued

116. Social Annotation to enhance Learning and Assessment in higher Education (book chapter), D. Lebow, D. Lick, H. Hartman, C. Dalglish, O. Grundmann, in *Educating Educators with Social Media*, Charles Wankel (ed.), Emerald Publishing, 2011. ISBN: 9780857246493.

2010

117. Forensic Foundations, O. Grundmann, D. Wielbo, N. Toffolo, I. Tebbett, *Forensic Technology Review*, 2010, 186-189.
118. The gut microbiome and pre-systemic metabolism: current state and evolving research, O. Grundmann, *Journal of Drug Metabolism & Toxicology*, 2010, November;1:104.
119. Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome, O. Grundmann, S. Yoon, B. Moshiree, *Current Pharmaceutical Design*, 2010, November;16(33): 3638-3645. PMID: 21128902.
120. Propofol: An Analytical and Medico-legal Challenge, O. Grundmann, *Forensic Magazine*, 2010, October/November;7(5):13-15.
121. The Implementation and Growth of an International Online Forensic Science Graduate Program at the University of Florida, O. Grundmann, D. Wielbo, I. Tebbett, *Journal of College Science Teaching*, 2010, September/October;40(1): 34-40.
122. Restoration of radiation therapy-induced salivary gland dysfunction in mice by post therapy IGF-1 administration, O. Grundmann, J.L. Fillinger, K.R. Victory, R. Burd, K.H. Limesand, *BMC Cancer*, 2010, August;10:417. PMID: 20698985.
123. Insulin-Like growth factor-1 preserves salivary gland function after fractionated radiation, K.H. Limesand, J.L. Avila, K. Victory, H.H. Chang, Y.J. Shin, O. Grundmann, R.R. Klein, *International Journal of Radiation Oncology, Biology, Physics*, 2010, October;78(2):579-586. PMID: 20638195.
124. Mechanism of St. John's wort extract (STW3-VI) during chronic restraint stress is mediated by the interrelationship of the immune, oxidative defense, and neuroendocrine system, O. Grundmann, Y. Lv, O. Kelber, V. Butterweck, *Neuropharmacology*, 2010, March-April;58(4-5): 767-773. PMID: 20036263.
125. Irritable Bowel Syndrome (IBS) - epidemiology, diagnosis, and treatment - an update for healthcare practitioners, O. Grundmann, S. Yoon, *Journal of Gastroenterology and Hepatology*, 2010, April;25(4): 691-699. PMID: 20074154.

2009

126. Sensitivity of salivary glands to radiation: From animal models to therapies, O. Grundmann, G.C. Mitchell, K.H. Limesand, *Journal of Dental Research*, 2009, October;88(10): 894-903. PMID: 19783796.
127. Kaempferol from the leaves of *Apocynum venetum* possesses anxiolytic activities in the elevated plus maze test in mice, O. Grundmann, J. Nakajima, K. Kamata, S. Seo, V. Butterweck, *Phytomedicine*, 2009, April;16(4): 295-302. PMID: 19303276.
128. Anxiolytic effects of a passion flower (*Passiflora incarnata* L.) extract in the elevated plus maze in mice, O. Grundmann, C. Wähling, C. Staiger, V. Butterweck, *Pharmazie*, 2009, January;64(1): 63-64. PMID: 19216234.
129. Deadly delicious – Mushroom poisoning, O. Grundmann, I. Tebbett, *Forensic Magazine*, 2009, February/March;6(1).

2009 continued

130. Radiation-induced salivary gland dysfunction results from p53-dependent apoptosis, J. Avila, O. Grundmann, R. Burd, K.H. Limesand, *International Journal of Radiation Oncology, Biology, Physics*, 2009, February;73(2): 523-529. PMID: 19147016.

2008

131. Anxiolytic activity of a phytochemically characterized *Passiflora incarnata* extract is mediated via the GABA-ergic system, O. Grundmann, J. Wang, G.P. McGregor, V. Butterweck, *Planta Medica*, 2008, December;74(15): 1769-1773. PMID: 19006051.
132. Ricin on the rise – are we prepared? O. Grundmann, I. Tebbett, *Forensic Magazine*, 2008, June/July;5(3): 25-28.

2007

133. *Apocynum venetum* L., a traditional herbal drug with up-to-date pharmacological effects, O. Grundmann, V. Butterweck, *Zeitschrift für Phytotherapie*, 2007, October;28(5): 215-222.

2007 continued

134. *Salvia divinorum* and Salvinorin A: An Update on Pharmacology and Analytical Methodology, O. Grundmann, S.M. Phipps, I. Zadezensky, V. Butterweck, *Planta Medica*, 2007, August;73(10): 1039-46. PMID: 17628834.
135. Hypothermic effects of hops are antagonized with the competitive melatonin receptor antagonist luzindole in mice, V. Butterweck, A. Brattstroem, O. Grundmann, U. Koetter, *Journal of Pharmacy and Pharmacology*, 2007, April;59(4): 549-552. PMID: 17430638.
136. Anti-anxiety Effects of *Apocynum venetum* L. in the Elevated Plus Maze test, O. Grundmann, J. Nakajima, S. Seo, V. Butterweck, *Journal of Ethnopharmacology*, 2007, April;110(3): 406-411. PMID: 17101250.

2006

137. Effects of St. John's wort extract and single constituents on stress induced hyperthermia in mice, O. Grundmann, O. Kelber, V. Butterweck, *Planta Medica*, 2006, December;72(15): 1366-1371. PMID: 17051457.
138. Antidepressant effect of extracts from *Ginkgo biloba* leaves in behavioral models, H. Sakakibara, K. Ishida, O. Grundmann, J. Nakajima, S. Seo, V. Butterweck, Y. Minami, S. Saito, Y. Kawai, Y. Nakaya, J. Terao, *Biological & Pharmaceutical Bulletin*, 2006, August;29(8): 1767-1770. PMID: 16880641.

Multimedia interviews

2023

The rest of the US needs to follow Florida's lead and start regulating kratom extracts, December 2023, <https://thehill.com/opinion/healthcare/4379508-the-rest-of-the-us-needs-to-follow-floridas-lead-and-start-regulating-kratom-extracts/>

What You Should Know About the Potential Risks of Kratom, July 2023, <https://www.nytimes.com/2023/07/26/well/mind/kratom-health-risks.html>

2022

EMG-Health, Episode 99, Can You Trust Your Gut?, April 2022, <https://www.emg-health.com/omnipresent/emg-health-podcast-can-you-trust-your-gut/>

Kratom consumer protection act will add much needed regulation to the marketplace, Opinion, February 2022, Tampa Bay Times, <https://www.tampabay.com/opinion/2022/02/05/kratom-consumer-protection-act-will-add-much-needed-regulation-to-the-marketplace-column/>

Hamilton Morris talks kratom prohibition, botany, and pharmacology, February 2022, <https://www.youtube.com/watch?v=iXdfnVEFGP8>

Psychedelics Today, January 2022, PT281 – Oliver Grundmann, Ph.D. – A Thorough Exploration of Kratom, <https://psychedelictoday.com/2022/01/04/pt281/>

2021

Center for Teaching Excellence, University of Florida, Teaching Beyond the Podium Podcast Series, September 2021, Academic Integrity in the Online Environment, <https://teach.ufl.edu/resource-library/teachingbeyondthepodium/>

The New York Times, August 20, 2021, Is Aloe a Sham? <https://www.nytimes.com/2021/08/20/well/aloe-sunburn.html>

Kratom: Research Findings and Methods of Use with Dr. Oliver Grundmann, Plant Medicine Podcast with Dr. Lynn Marie Morski, <https://www.plantmedicine.org/podcast/kratom-research-and-use-dr-oliver-grundmann>

Kratom Science, Hamilton Morris, Soren Shade, and Dr. Oliver Grundmann Talk Kratom and a New Survey, <https://www.kratomscience.com/podcast/hamilton-morris-soren-shade-and-dr-oliver-grundmann-talk-kratom-and-a-new-survey/>

WCJB ABC 20, April 15, 2021, Rare hallucinogen 'DMT' found in relation to Keystone Heights drug lab investigation. <https://www.wcjb.com/2021/04/15/rare-hallucinogen-dmt-found-in-relation-to-keystone-heights-drug-lab-investigation/>

Tucson Lifestyle, April 15, 2021, Kratom: Love It ... or Leave It? https://www.tucsonlifestyle.com/health/kratom-love-it-or-leave-it/article_7983ee7a-9e36-11eb-ba8b-0ff7cc76fadf.html

2020

Kratom Science, Episode 40, November 11, 2020, <https://www.kratomscience.com/podcast/40-dr-oliver-grundmann/>

Adventures through the Mind Episode 121, All about Kratom, May 7, 2020, <https://www.jameswjesso.com/all-about-kratom-dr-oliver-grundmann-attmind-121/>

2020 continued

Practical Pain Management, February 4, 2020, Is Kratom a Viable Alternative to Opioids? <https://www.practicalpainmanagement.com/patient/treatments/alternative/kratom-viable-alternative-opioids>

Wired, January 22, 2020, Release the Kratom: Inside America's Hottest New Drug Culture. <https://www.wired.com/story/release-the-kratom-inside-drug-culture/>

2019

NBC News, October 16, 2019, What is kratom? The popular herbal supplement has caught flak from the FDA. <https://www.nbcnews.com/health/health-news/what-kratom-popular-herbal-supplement-has-caught-flak-fda-n1066526>

Say Why to Drugs Podcast with Dr. Suzi Gage: Kratom, June 19, 2019. <https://play.acast.com/s/saywhytodrugs/0fa1f5af-89bd-4bff-82f8-bd9f67634b74>

KMOV4, April 25, 2019, Kratom Craze: After wife's death, Franklin County man seeks ban on popular substance. https://www.kmov.com/news/kratom-craze-after-wife-s-death-franklin-county-man-seeks/article_e6b63810-6778-11e9-9cf9-ef700524f44b.html

Science News, April 19, 2019, The herbal supplement kratom comes with risks. <https://www.sciencenews.org/article/herbal-supplement-kratom-comes-risks>

The New York Times, April 17, 2019, Opioid Users Call Kratom a Godsend. The F.D.A. Says It's a Menace. <https://www.nytimes.com/2019/04/17/us/kratom-overdose-deaths.html>

2018

Herbalgram, 119 (July-September), 2018, Kratom Crackdown: FDA Intensifies Warnings with Limited, Inconclusive Data

WHYY The Pulse, May 31, 2018, Fears and evidence clash in the battle over kratom. <https://whyy.org/segments/fears-and-evidence-clash-in-the-battle-over-kratom/>

ABC Action News, March 14, 2018, Addictive drug or alternative to break the habit? Doctors dispute FDA about effects of Kratom. <https://www.abcactionnews.com/news/thenow/addictive-drug-or-alternative-to-break-the-habit-doctors-dispute-fda-about-effects-of-kratom>

Natural Products Insider, March 13, 2018, Researchers Combat FDA Stance on Kratom, Favor its Regulation as Supplement. <https://www.naturalproductsinsider.com/ingredients/researchers-combat-fda-stance-kratom-favor-its-regulation-supplement>

Pew Trust Stateline Update, March 8, 2018, Scientists Call on FDA to Regulate, Not Ban, Kratom. <http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2018/03/08/scientists-call-on-fda-to-regulate-not-ban-kratom>

The Scientist, February 7 2018. FDA Declares Kratom an Opioid. We're Here to Explain What It Does. <https://www.the-scientist.com/?articles.view/articleNo/51593/title/FDA-Declares-Kratom-an-Opioid--We-re-Here-to-Explain-What-It-Does-/>

Consumer Reports, February 6 2018. The Dangers of Taking Kratom, <https://www.consumerreports.org/dietary-supplements/the-dangers-of-taking-kratom/>

2017

Chicago Tribune, December 7 2017. As kratom use surges, some states enact bans, <http://www.chicagotribune.com/news/nationworld/sns-tns-bc-kratom-bans-20171207-story.html>

ASBMB Today, July 1 2017. The science behind kratom's strange leaves, <http://www.asbmb.org/asbmbtoday/201706/Features/KRATOM/>

Independent, May 13 2017. Alabama becomes the sixth state to ban Kratom, <http://www.independent.co.uk/news/world/americas/alabama-becomes-the-sixth-state-to-ban-kratom-a7028911.html>

2016

WBUR, September 30 2016. Impending Ban On Herbal Painkiller Kratom Could Hamper Research, <http://www.wbur.org/commonhealth/2016/09/30/herbal-painkiller-kratom-ban-research>

Vice, September 26 2016. The DEA Is About to Make Life Even More Dangerous for Heroin Users, https://www.vice.com/en_us/article/ggkyjw/kratom-opioids-dea-scheduling-ban

STAT Politics, September 8 2016. Kratom ban will hinder studies of the plant for treating pain or addiction, researchers say, <https://www.statnews.com/2016/09/08/kratom-ban-hinders-research/>

Scientific American, August 31 2016. DEA Set to Ban Chemicals Contained in Kratom, <https://www.scientificamerican.com/article/dea-set-to-ban-chemicals-contained-in-kratom/>

Associated Press, May 20 2016. States ban kratom supplement over abuse worries, <https://apnews.com/6e37d246c7144e0080eb3d7cdac8684e/states-ban-kratom-supplement-over-abuse-worries>

Business Insider, January 4 2016. People are flocking to Florida bars for a legal but dangerous drug, <http://www.businessinsider.com/what-is-kratom-2016-1>

Awards & Distinctions

2023

Teaching & Service Award Winner 2022-23, College of Pharmacy, University of Florida

2022

Phi Lambda Sigma Pharmacy Leadership Society, Beta Tau Chapter, Midwestern University

Outstanding Teaching Team PharmD Year 2, College of Pharmacy, University of Florida

Faculty Diversity, Inclusion, and Health Equity (DIHE) Award, College of Pharmacy, University of Florida

Faculty Advisor of the Year, College of Pharmacy, University of Florida

Media Excellence Award, College of Pharmacy, University of Florida

President Elect, American College of Clinical Pharmacology (ACCP), 2022-2024

2021

Outstanding Teaching Team PharmD Year 2, College of Pharmacy, University of Florida

2020

Outstanding Teaching Team PharmD Year 1, College of Pharmacy, University of Florida

Secretary, American College of Clinical Pharmacology (ACCP), 2020-2022

Exemplary Online Award, PHA6432 Fundamentals of Pharmaceutical Chemistry, UF Center for Teaching Excellence

2019

Recognition Award, Arizona Board of Pharmacy

Regent, American College of Clinical Pharmacology (ACCP), 2020-2024

UF Career Influencer Award, University of Florida

Outstanding Teaching Team PharmD Year 2, College of Pharmacy, University of Florida

2018

Fellow of the American College of Clinical Pharmacology (ACCP)

Outstanding Publication in Teaching Innovation or Clinical Practice Innovation, College of Pharmacy, University of Florida

Outstanding Teaching Team PharmD Years 1, 2, & 3, College of Pharmacy, University of Florida

2017

Outstanding Teaching Team PharmD Year 2, College of Pharmacy, University of Florida

American College of Clinical Pharmacology Excellence in Achievement recognition for STYP leadership

2015

Janet K. Poley Award for Innovation and Leadership in Distance Education, American Distance Education Consortium

2013

Poster Award, mentor of undergraduate students, UF College of Nursing Research day

2012

UF Open Access award for editorial services and the Journal of Alternative Medicine Studies

2007

Poster award recipient of the American Society of Pharmacognosy

2006

Travel grant recipient of the Society for Medicinal Plant research

2005

Summer fellowship of the Japan Society for the Promotion of Science and the German Academic Exchange Service

Certificate of Academic Achievement by the President of the University of Florida

Professional Memberships

American Association of Colleges of Pharmacy

Chair of the Resolutions Committee of the Continuing Professional Development Section (2020-2022), Member of the Resolutions Committee of the Continuing Professional Development Section (2023-2024)

American Distance Education Consortium (ADEC)

Chair of the Executive Board (2015-17)

American Society of Pharmacognosy (ASP)

German Association of Pharmacy (DPhG)

American Association of Pharmaceutical Scientists (AAPS)

Secretary and historian of the UF Student chapter (2006-2007)

American College of Clinical Pharmacology (ACCP), Fellow (FCP)

Member Student Outreach committee (SOC), renamed Student, Trainee, Early-Stage Professionals (STEP) Committee (2016-20), co-chair (2018-2020); co-chair Education committee (2020-2022); Member Inclusivity, Diversity & Equity (IDE) Committee (2021-2023); Board of Regents (2020-2024); Secretary (2020-2022); President Elect (2022-2024); co-chair Annual Meeting planning committee (2022); Member Annual Meeting planning committee (2021, 2023)

Society for Medicinal Plant Research

National Scholar Honors Society

American Chemical Society (ACS) (2009-2020)

National Science Teaching Association (NSTA)

Member (2014-17), Chair of the International Advisory Board (2015-16)

Member (2010-2013), Committee on College Science Teaching

Member (2019-2022), Interim Chair of the Advisory Board on Journal of College Science Teaching (2022)

American Academy of Clinical Toxicology (AACT)

Member Section Diversity, Equity & Inclusion

Subcommittee chair of Forensic Toxicology Special Interest Group

Society of Forensic Toxicologists (SOFT)

Full member

College on Problems of Drug Dependence (CPDD)

Member (2024-2026), Travel Awards Committee

Community outreach/extracurricular activities

Conference committee member, American College of Clinical Pharmacology 2023 meeting, Bellevue, WA (September 2023)

Conference co-chair, American College of Clinical Pharmacology 2022 meeting, Bethesda, MD (September 2022)

Conference committee member, American College of Clinical Pharmacology 2021 meeting, virtual (September 2021)

Conference Co-Chair, American Distance Education Consortium EDFuture conference 2016, University of California Los Angeles, Los Angeles, CA (September 2016)

Conference chair, 11th Global Conversations in Science Education Conference, National Science Teachers Association, Nashville, TN (March 2016)

Chair, International Advisory Board, National Science Teachers Association (June 2015 - June 2016)

Conference Co-Chair, American Distance Education Consortium symposium 2015, Oregon State University, Corvallis, OR (May 2015)

Volunteer, Mesa Police Department Forensic Services, Mesa, AZ (March 2015 - June 2018)

Grand judge at the Intel Science and Engineering Fair, Phoenix, AZ (May 2013)

Volunteer judge for Arizona "Project citizen", Arizona Foundation for Legal Services & Education (2011 - present)

Local middle and high school presentations on forensic sciences and drug abuse (2009 - present)

Workshop "Strengthening Forensic Science in the United States", National Science Foundation, Washington, D.C. (December 2012)

Additional Qualifications

Ad-hoc manuscript reviewer for:

Planta Medica (2008-present)
BioMed Central Complementary and Alternative Medicine (2010-present)
Journal of Dietary Supplements (2010-present)
Nutrition and Cancer (2012-present)
Journal of Ethnopharmacology (2013-present)
PLOS One (2015-present)
European Journal of Pharmaceutical Sciences (2016-present)
Phytomedicine (2017-present)
Drug & Alcohol Dependence (2017-present)
International Journal of Drug Policy (2018-present)
Journal of Psychoactive Drugs (2018-present)
Addiction (2018-present)
Journal of Clinical Pharmacology (2018-present)
Clinical Therapeutics (2019-present)

Section Editor, *Current Addiction Reports*, Section Kratom
(2022-2023)

Associate & Guest Editor, *Frontiers in Pharmacology*, Section Ethnopharmacology
(2020-present)

Member of the Editorial Board and Associate Section Editor of the *International Journal of Environmental Research and Public Health*, Toxicology and Public Health section (2019-present)

Member of the Editorial Board of the *European Medical Journal - Gastroenterology*
(2019-present)

Member of the Editorial Board of the *World Journal of Translational Medicine*
(2013-present)

Contributing Associate Editor-in-Chief of the *World Journal of Gastroenterology*
(2011-2014)

Peer reviewer, Natural Standard Research Collaboration (2011-present)

Peer reviewer, Health Research Board, Republic of Ireland (2011)

Peer reviewer, Qatar National Research Fund, Qatar (2019)

Peer reviewer, Hetzler Stiftung, Germany (2022)